Wuhan Boruida Biotechnology

Wuhan Boruida Biotechnology is a clinical-stage biopharmaceutical company based in Wuhan, China, dedicated to the development of next-generation immune cell therapies. The company focuses on chimeric antigen receptor T-cell (CAR-T) technologies, particularly dual-targeting and multi-targeting approaches to address tumor heterogeneity and antigen escape. Its lead program, BRD-01, is a CD19/CD22 dual-target CAR-T therapy designed for patients with relapsed or refractory B-cell malignancies. Boruida's pipeline also includes candidates targeting BCMA for multiple myeloma and CD7 for T-cell malignancies. By integrating advanced cell engineering and clinical translation, the company aims to provide curative treatments for hematological cancers and solid tumors.